uniQure (NASDAQ:QURE) Short Interest Down 21.2% in December

uniQure (NASDAQ:QURE) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,390,000 shares, a drop of 21.2% from the December 15th total of 4,300,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is presently 1.6 days.

uniQure Stock Up 6.7 %

NASDAQ QURE traded up $0.89 during trading hours on Wednesday, reaching $14.12. 1,022,110 shares of the company traded hands, compared to its average volume of 1,446,030. The stock has a market capitalization of $688.25 million, a PE ratio of -2.85 and a beta of 0.41. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a 50 day moving average of $11.70 and a two-hundred day moving average of $8.20.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts expect that uniQure will post -3.82 earnings per share for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in QURE. Vanguard Personalized Indexing Management LLC grew its stake in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in shares of uniQure during the fourth quarter worth approximately $88,000. Geode Capital Management LLC grew its holdings in uniQure by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares in the last quarter. Finally, American Century Companies Inc. increased its position in uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 8,642 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Stifel Nicolaus raised their price target on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.88.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.